You are using a browser that is not supported by this site. The site will not function properly. Please switch to the latest version of a supported browser such as Chrome, Safari, Edge, or Firefox to use this site.
Pathophysiology of VOD and the proposed mechanism of action of Defitelio
Learn more about VOD and Defitelio from key clinical expertsa
Veno-Occlusive Disease (VOD): Signs of Renal or Pulmonary Dysfunction and Key Diagnostic Considerations
Find information on ordering and reimbursement for DefitelioLearn more
For more pharmacy information, including preparation instructions, download a PDF of the Defitelio Pharmacy Dosing, Preparation, and Ordering GuideDownload
For more information, please call Jazz Pharmaceuticals Customer Service at 1-800-833-3533
aThe videos above are part of a presentation featuring faculty who are paid consultants of Jazz Pharmaceuticals.
Defitelio® (defibrotide sodium) is indicated for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT).
IMPORTANT SAFETY INFORMATION
Defitelio is contraindicated in the following conditions:
- Concomitant administration with systemic anticoagulant or fibrinolytic therapy
- Known hypersensitivity to Defitelio or to any of its excipients
Warnings and Precautions
Defitelio may increase the risk of bleeding in patients with VOD after HSCT. Do not initiate Defitelio in patients with active bleeding. Monitor patients on Defitelio for signs of bleeding. If bleeding occurs, withhold or discontinue Defitelio.
Concomitant systemic anticoagulant or fibrinolytic therapy may increase the risk of bleeding and should be discontinued prior to Defitelio treatment. Consider delaying Defitelio administration until the effects of the anticoagulant have abated.
Hypersensitivity reactions including rash, urticaria, and angioedema have occurred in less than 2% of patients treated with Defitelio. One case of an anaphylactic reaction was reported in a patient who had previously received Defitelio. Monitor patients for hypersensitivity reactions, especially if there is a history of previous exposure. If a severe hypersensitivity reaction occurs, discontinue Defitelio, treat according to the standard of care, and monitor until symptoms resolve.
Most Common Adverse Reactions
The most common adverse reactions (incidence ≥10% and independent of causality) with Defitelio treatment were hypotension, diarrhea, vomiting, nausea, and epistaxis.Please see full Prescribing Information.
AML=acute myeloid leukemia; MOA=mechanism of action; VOD=veno-occlusive disease.